Asia/Oceania Jan 13, 2023 In Brief This Week: Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda, Micronoma Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 10, 2023 Prenetics' ACT Genomics Profiling Test for Solid Tumors Receives FDA Clearance Jan 6, 2023 METiS Inks Exclusive Licensing Agreement With Evopoint Biosciences for SOS1 Inhibitor Jan 3, 2023 China's NMPA Accepts New Drug Application for Legend Biotech, Janssen's Carvykti Dec 30, 2022 Esophageal Cancer Molecular Study Highlights Tumor Subtypes, Treatment Response Markers Dec 28, 2022 Mission Bio, Abiosciences to Develop Analytics For Studying Hematologic Cancers Dec 27, 2022 Anuva, Max Healthcare Conducting Genomics Research to Advance Precision Medicine Dec 22, 2022 FDA Clears Iaso Biotherapeutics for US Trials of BCMA-Targeted CAR-T Therapy in Multiple Myeloma Dec 22, 2022 Merck Pays $175M Upfront for Rights to Seven Kelun-Biotech Antibody-Drug Conjugate Candidates Dec 21, 2022 Japanese Lung Cancer Genomic Screening Project Expands in Asia-Pacific Dec 19, 2022 SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit Dec 16, 2022 Prenetics to Take Majority Stake in ACT Genomics Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Dec 6, 2022 Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Dec 6, 2022 Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody Dec 1, 2022 Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Nov 29, 2022 ICPO Foundation, PreMIT Collaborate to Establish Theranostic Centers Nov 28, 2022 SeekIn Receives CE-IVD Mark for Cancer Recurrence Monitoring Test Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer